 Patients will be enrolled in the study after all study-specific entry criteria are met and informed consent is obtained. Patients will be required to attend regular clinic visits to receive study medication and have their status monitored. Patients will also be required to have radiologic tumor assessments performed at multiple times throughout the study. A detailed explanation can be provided by the study physician Investigator conducting this study. Trabectedin at a starting dose of 0.58 mgm2 will be given to patients intravenously i.v. as a 3-hour infusion every week for 3 weeks on Days 1, 8, and 15 of a 4 week cycle via a central venous catheter also referred to as a central line which is a tube ie, catheter placed into a large vein. All patients will receive dexamethasone 10 mg i.v. 30 minutes prior to each trabectedin infusion. Patients may receive multiple cycles of trabectedin in the absence of disease progression. 